Comparative Study of Prostatic Carcinoma Bone Metastasis among Japanese in Japan and Japanese Americans and Whites in Hawaii
Metastatic prostate carcinomas in autopsy cases from three populations 49 cases of indigenous Japanese, 29 cases of Japanese Americans and 14 from whites in Hawaii) were compared in terms of their clinicopathological, immunohistochemical (tenascin and ras p21) and lectin binding (Helix Pomatia antigen, HPA) properties. Only the clinicopathological features were analyzed in the cases of whites in Hawaii.
The results indicate that poorly differentiated carcinoma is less common, whereas distant metastasis is more frequent, in indigenous Japanese. Some of the Japanese-American cases with poorly differentiated carcinomas did not show any distant metastases. HPA and ras p21 expression are more common, but tenascin is less common in indigenous Japanese. HPA expression is more common in cases with metastasis, especially with metastasis to the bone and other organs, than nonmetastatic cases. Prostatic cancer cases in indigenous Japanese were more aggressive biologically than those in Japanese Americans, but no phenotypic differences were seen relevant to the presence or absence of bone metastases.
KeywordsProstatic Cancer Bone Metastasis Autopsy Case Lectin Binding Metastatic Behavior
Unable to display preview. Download preview PDF.
- 1.Yatani R., Takanari H., Miura S., Nakano H., Seto K., Clinicopathological study on prostatic cancer, in: “Basic and Clinical Research on Prostatic Cancer,” pp 35–45(in Japanese) Shida K., ed., Kinbarasyuppan, Tokyo (1988).Google Scholar
- 2.Yatani R., Kusano K., Shiraishi T., Takuji H., Stemmermann G.N., Latent prostatic arcinoma: pathological and epidemiological aspects, Jpn. J. Clin. Oncol. 19:226–319 (1989).Google Scholar
- 4.Liotta L.A., Tumor invasion and metastasis-role of the extracellular matrix, Cancer Res. 34:187–220 (1986).Google Scholar
- 6.Yoshida K., Hamatani E., Koide H., Nakamura N., Akiyama M., Tsuchiyama H., Nakayama E., Shiku H., Preparation of antiras MW 21,000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers. Cancer Res. 48:5503–5509, (1988).PubMedGoogle Scholar
- 10.Sakakura T., Jing N., Saga Y., Tsukamoto T., Kusakabe M., Role of extracellular matrix tenascin in carcino-embryonic development, Taisya 27:137–146 (1990). (in Japanese)Google Scholar
- 17.Tahara H., Yasui W., Taniyama S., Ochiai A., Yamamoto T., Nakajo S., Yamamoto M., Ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis, Jap. J. Cancer Res. (GANN) 77:517–522 (1986).Google Scholar
- 19.Viola M.V., Fromowitz F., Oravez S., Deb S., Finkel G., Lundy J., Hand P., Thor A., Schlom J., Expression of ras oncogene p21 in prostate cancer, New Eng. J. 314:132–137 (1986).Google Scholar
- 20.Sumiya H., Akakura K., Fuse H., Shimazaki J., Expression of ras oncogene product (ras p21) in prostatic cancer, Jap. J. Clin. Urol. 41:703–705 (1987). (in Japanese)Google Scholar
- 26.Leathern A.J. and Brooks S.A. Predictive value of lectin binding on breast cancer recurrence and survival, Lancet 1054–1056 (1987).Google Scholar